Sangamo inks technology deal with Genentech

Sangamo BioSciences has inked a deal to provide Genentech with its zinc finger DNA-binding protein technology along with ZFP nucleases to generate cell lines with novel characteristics for protein pharmaceutical production purposes. The proteins regulate the work of genes in cells and can be targeted at specific genes linked to disease.

"We have engineered ZFNs to facilitate the efficient generation of production cell lines with altered traits," said Edward Lanphier, Sangamo's president and chief executive officer. "Our technology has the potential to change the speed and efficiency of cell engineering to meet the increased demand for proteins in a variety of industries including pharmaceutical protein manufacturing."

- check out the release on the deal
- here's the AP report for more information

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.